Taro recalls skin treatment cream from US, Puerto Rico markets


Taro Pharmaceuticals, the Israel -based subsidiary of Sun Pharmaceuticals, has recalled nearly 40,000 tubes of Fluorouracil topical cream, used to treat various skin conditions, from the American market.

Taro Pharmaceuticals USA Inc has voluntarily recalled 39,982 tubes of Fluorouracil Topical Cream USP from the US and Puerto Rico markets, US Food and Drug Administration (USFDA) said in its enforcement report.

The reason for the class II recall is that 'product lacks stability', it added.

As per the USFDA, class II recalls are done in a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Sun Pharma had acquired a controlling stake in Taro in September, 2010. The Mumbai-based firm currently holds 66.5 per cent stake in Taro.

Topical fluorouracil is used to treat certain skin conditions in which cells are multiplying rapidly. It is used to treat cancerous or precancerous conditions including solar keratoses, actinic keratosis and superficial basal cell carcinoma.

Please read our terms of use before posting comments
TERMS OF USE: The views, opinions and comments posted are your, and are not endorsed by this website. You shall be solely responsible for the comment posted here. The website reserves the right to delete, reject, or otherwise remove any views, opinions and comments posted or part thereof. You shall ensure that the comment is not inflammatory, abusive, derogatory, defamatory &/or obscene, or contain pornographic matter and/or does not constitute hate mail, or violate privacy of any person (s) or breach confidentiality or otherwise is illegal, immoral or contrary to public policy. Nor should it contain anything infringing copyright &/or intellectual property rights of any person(s).
comments powered by Disqus